Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hexachlorophene

FDA-approved product (soap, topical), marketed as "germa-Medica ""mg""", Dial, E-Z Scrub and 13 more.

Registered studies
3
Lab records
6
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Hexachlorophene
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Hexachlorophene. Its therapeutic class is shown instead.

WHO therapeutic group
Phenol and derivatives
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D08AE01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli17.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae10.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis20.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

3registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 6 of 6 lab records
Open Hexachlorophene in ChEMBL Registered studies below
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hexachlorophene with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA

    NCT00532324 · start 2008-02

    Registered record
    Registry ID
    NCT00532324
    Conditions
    Staphylococcus Aureus
    Interventions
    CA-MRSA Decolonization
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-02
    Completion
    2013-10
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus
    InterventionCA-MRSA Decolonization
    PhaseNot applicable
    Registry statusCompleted

  • Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons

    NCT00631566 · start 2007-05

    Registered record
    Registry ID
    NCT00631566
    Conditions
    HIV Infections; Staphylococcal Infections
    Interventions
    Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-05
    Completion
    2017-10
    Enrolment
    550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Staphylococcal Infections
    InterventionMupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections

    NCT01049438 · start 2006-08

    Registered record
    Registry ID
    NCT01049438
    Conditions
    Methicillin Resistant Staphylococcus Aureus Skin Infections
    Interventions
    nasal mupirocin; topical 3% hexachlorophene body wash; oral anti-MRSA antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-08
    Completion
    2009-09
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethicillin Resistant Staphylococcus Aureus Skin Infections
    Interventionnasal mupirocin; topical 3% hexachlorophene body wash; oral anti-MRSA antibiotic
    PhaseNot applicable
    Registry statusCompleted